Ayurveda’s View on the Microbiome and Its Role in Crohn’s Disease

Ayurveda’s View on the Microbiome and Its Role in Crohn’s Disease

Crohn’s disease is a complex, chronic inflammatory bowel disease (IBD) characterized by inflammation along the digestive tract, which can lead to symptoms like abdominal pain, diarrhea, fatigue, and nutrient deficiencies (Baumgart & Sandborn, 2012). Modern science links Crohn’s disease to immune dysregulation and microbial imbalances in the gut, often described as “dysbiosis” (Frank et al., 2007). Ayurveda, while not directly referencing the microbiome, has long emphasized gut health, digestion, and toxin management as fundamental to overall wellness (Lad, 2002). EliteAyurveda’s approach combines these Ayurvedic principles with the modern understanding of gut bacteria to support patients in managing Crohn’s disease holistically (Sharma & Chandola, 2011).

Microbiome and Its Role in Crohn’s Disease

Understanding the Microbiome in Ayurveda: Agni, Ama, and Dosha Balance

Ayurveda does not explicitly mention the microbiome but offers a deep understanding of gut health through concepts like Agni (digestive fire), Ama (toxins), and dosha balance (Frawley, 2000). These principles align closely with what we now know about the microbiome’s influence on digestion, immunity, and inflammation (Peterson et al., 2015).

• Agni (Digestive Fire): Agni represents the body’s ability to digest food, absorb nutrients, and transform these into energy. When Agni is strong, it creates a healthy digestive environment that supports beneficial gut flora (Lad, 2002). In Crohn’s disease, weak Agni can lead to poor digestion, nutrient malabsorption, and a disrupted gut environment, fostering harmful bacteria and inflammation (Sharma & Chandola, 2011).
• Ama (Toxins): Ama is the result of incomplete digestion and can accumulate in the digestive tract when Agni is weak. In Ayurveda, Ama represents toxic buildup that clogs the body’s channels and disrupts natural processes, often correlating with dysbiosis in the gut (Mishra, 2004). Excess Ama creates an environment where inflammation can flourish, worsening Crohn’s symptoms (Frawley, 2000).
• Doshic Influence on Gut Health: The doshas—Vata, Pitta, and Kapha—each impact the digestive process and gut health uniquely. Imbalances in these doshas can disrupt the gut flora, impair Agni, and contribute to the development and severity of Crohn’s symptoms (Pole, 2013).

The Microbiome and Crohn’s Disease Through an Ayurvedic Lens

In Ayurveda, Crohn’s disease is seen as a result of weak digestive fire, toxic accumulation, and imbalances in the doshas, which disrupt the gut environment and weaken immunity (Lad, 2002). This perspective aligns with the modern understanding that microbial imbalances can lead to immune dysregulation and inflammation (Frank et al., 2007). Here’s how Ayurveda interprets the microbiome’s role in Crohn’s disease:

1. Weakened Agni and Microbial Imbalance

In Crohn’s disease, weak Agni often leads to improper digestion, creating fermentation, gas, and undigested food residues (Mishra, 2004). This undigested food encourages the growth of harmful bacteria, worsening symptoms and increasing gut inflammation (Peterson et al., 2015).

• Ayurvedic Insight: Strengthening Agni through diet, herbal support, and lifestyle changes helps maintain a balanced gut environment where beneficial bacteria can thrive (Frawley, 2000). This, in turn, reduces inflammation and supports digestive health, addressing symptoms of Crohn’s disease (Sharma & Chandola, 2011).

2. Ama and Dysbiosis

Ama, or toxins resulting from incomplete digestion, disrupts gut health by creating a toxic environment that favors harmful bacteria and leads to dysbiosis (Mishra, 2004). In Crohn’s disease, Ama accumulation contributes to inflammation, pain, and frequent flare-ups (Pole, 2013).

• Ayurvedic Approach: Ayurveda emphasizes clearing Ama through detoxifying herbs and dietary modifications to improve digestion and support microbial balance (Lad, 2002). Treatments focus on eliminating Ama, promoting a healthier gut environment, and reducing inflammation (Sharma & Chandola, 2011).

3. Doshic Imbalances and Their Impact on Gut Health

Each dosha affects digestion and the gut microbiome differently. For example:

• Vata Imbalance: Vata governs movement and contributes to bloating, irregular bowel movements, and sensitivity in digestion (Frawley, 2000). When Vata is high, it can lead to erratic bowel patterns, cramps, and inflammation, all common in Crohn’s disease (Lad, 2002).
• Pitta Imbalance: Pitta controls metabolism and heat. When Pitta is aggravated, it can lead to excessive acid, inflammation, and heat, creating an environment of irritation and inflammation in the gut—symptoms often seen in Crohn’s disease (Pole, 2013).
• Kapha Imbalance: Kapha governs structure and moisture. When Kapha is high, it can cause mucus buildup, sluggish digestion, and poor immune response (Dass, 2013). Kapha imbalances may lead to congestion and increased sensitivity in the digestive system (Mishra, 2004).

Our approach includes balancing these doshas to stabilize Agni and create a favorable environment for gut health, reducing symptoms and supporting overall well-being in Crohn’s patients (Sharma & Chandola, 2011).

EliteAyurveda’s Approach to Managing Crohn’s Disease Through Microbiome Health

EliteAyurveda’s holistic approach to Crohn’s disease incorporates Ayurvedic principles of digestion, detoxification, and doshic balance to promote a healthy gut environment and manage symptoms (Pole, 2013). Our treatments aim to strengthen Agni, reduce Ama, and maintain a balanced microbiome, using personalized herbal support and lifestyle guidance (Sharma & Chandola, 2011).

1. Customized Diet for Digestive Balance and Microbiome Health

In Ayurveda, diet is central to managing doshic balance and supporting gut health (Lad, 2002). EliteAyurveda tailors dietary recommendations to each patient’s constitution, doshic imbalance, and symptoms.

• Pitta-Pacifying Foods: Crohn’s disease often involves Pitta-related inflammation. Cooling foods like cucumbers, aloe vera, and leafy greens help calm inflammation and reduce heat in the gut (Frawley, 2000).
• Vata-Stabilizing Foods: Warm, nourishing foods like soups, stews, and cooked grains provide grounding and hydration, helping to stabilize Vata and improve digestion (Dass, 2013).
• Avoiding Kapha-Aggravating Foods: Foods that increase Kapha, such as dairy, fried foods, and heavy sugars, are avoided to prevent mucus buildup and digestive sluggishness (Mishra, 2004).

2. Personalized Ayurvedic Herbal Medications

Our Ayurvedic herbal treatments are tailored to each patient’s needs, designed to reduce inflammation, cleanse Ama, and support a balanced microbiome without side effects (Sharma & Chandola, 2011).

• Targeted Herbal Support: Cooling and anti-inflammatory herbs reduce Pitta-related inflammation, while grounding herbs stabilize Vata and support regular bowel movements (Frawley, 2000). These personalized herbal remedies foster a balanced gut environment, supporting beneficial bacteria and reducing harmful microbes (Pole, 2013).

3. Daily Routine (Dinacharya) for Gut Health and Immune Stability

A stable daily routine, or Dinacharya, helps maintain Agni and supports gut health (Lad, 2002). Regularity in meals, sleep, and exercise is essential for managing Crohn’s disease and promoting a healthy microbiome (Dass, 2013).

• Regular Meal Times: Eating at the same times each day strengthens Agni and improves digestion, reducing Ama accumulation (Mishra, 2004).
• Gentle Movement and Yoga: Exercise helps improve digestion, support lymphatic drainage, and maintain immune health, all of which are beneficial for managing Crohn’s disease (Pole, 2013).

4. Mind-Body Practices for Stress Reduction

Chronic stress impacts gut health, weakens Agni, and disrupts the microbiome (Kasture et al., 2013). Ayurveda’s mind-body approach helps manage stress, stabilizing immune responses and reducing the risk of flare-ups in Crohn’s disease (Lad, 2002).

• Meditation and Pranayama (Breathing Exercises): Mindfulness practices and breath control techniques like Nadi Shodhana (Alternate Nostril Breathing) help calm Vata and Pitta, supporting digestive health and promoting immune resilience (Frawley, 2000).

5. Seasonal Adjustments for Microbial and Digestive Stability

Each season affects doshic balance differently, which impacts digestion and gut health (Pole, 2013). Adjusting lifestyle and diet according to the seasons helps stabilize doshic fluctuations and maintain a healthy microbiome (Lad, 2002).

• Cooling Foods and Hydration for Summer: In warmer months, Pitta increases, so cooling foods, hydration, and avoiding heat exposure help maintain balance and prevent inflammation (Dass, 2013).
• Warming, Nourishing Foods for Winter: In colder months, Vata rises, so warm, cooked meals and grounding practices support digestion and gut health (Mishra, 2004).

Long-Term Benefits of Ayurvedic Management of Crohn’s Disease

Ayurvedic care provides sustainable relief by addressing root causes, supporting gut health, and promoting overall balance (Sharma & Chandola, 2011). Key long-term benefits include:

• Reduced Inflammation and Fewer Flare-Ups: Balancing doshas and reducing Ama minimizes immune reactivity and inflammation, leading to fewer Crohn’s flare-ups (Lad, 2002).
• Improved Digestion and Nutrient Absorption: By strengthening Agni and supporting a balanced microbiome, Ayurveda enhances digestion and nutrient absorption, reducing malabsorption and discomfort (Frawley, 2000).
• Holistic Well-Being: Ayurveda’s mind-body approach supports emotional stability, reduces stress, and promotes resilience, contributing to an improved quality of life for those with Crohn’s disease (Kasture et al., 2013).

Why Choose EliteAyurveda for Managing Crohn’s Disease?

EliteAyurveda offers a personalized, holistic approach to managing Crohn’s disease by addressing gut health, doshic balance, and the microbiome (Sharma & Chandola, 2011). Our expert practitioners create individualized care plans with herbal medications, dietary guidance, and lifestyle recommendations to help patients experience natural, sustainable relief and improved digestive health (Pole, 2013).

If you’re seeking a balanced, Ayurvedic approach to managing Crohn’s disease, EliteAyurveda provides compassionate, knowledgeable support for your healing journey (EliteAyurveda, n.d.).

Related-

Know more about ayurveda treatments for Crohn’s Disease

GET IN TOUCH

Schedule a Visit

Contact us

References

1.Le Berre C., Ananthakrishnan A.N., Danese S., Singh S., Peyrin-Biroulet L. Ulcerative Colitis and Crohn’s Disease Have Similar Burden and Goals for Treatment. Clin. Gastroenterol. Hepatol. 2020;18:14–23. doi: 10.1016/j.cgh.2019.07.005. [DOI] [PubMed] [Google Scholar]

2.Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. [DOI] [PubMed] [Google Scholar]

3.Roda G., Chien Ng S., Kotze P.G., Argollo M., Panaccione R., Spinelli A., Kaser A., Peyrin-Biroulet L., Danese S. Crohn’s disease. Nat. Rev. Dis. Primers. 2020;6:22. doi: 10.1038/s41572-020-0156-2. [DOI] [PubMed] [Google Scholar]

4.Boyapati R., Satsangi J., Ho G.T. Pathogenesis of Crohn’s disease. F1000Prime Rep. 2015;7:44. doi: 10.12703/P7-44. [DOI] [PMC free article] [PubMed] [Google Scholar]

5.Wilkins T., Jarvis K., Patel J. Diagnosis and management of Crohn’s disease. Am. Fam. Phys. 2011;84:1365–1375. [PubMed] [Google Scholar]

6.Feuerstein J.D., Cheifetz A.S. Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clin. Proc. 2017;92:1088–1103. doi: 10.1016/j.mayocp.2017.04.010. [DOI] [PubMed] [Google Scholar]

7.Torres J., Mehandru S., Colombel J.F., Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389:1741–1755. doi: 10.1016/S0140-6736(16)31711-1. [DOI] [PubMed] [Google Scholar]

8.Ruemmele F.M., Veres G., Kolho K.L., Griffiths A., Levine A., Escher J.C., Amil Dias J., Barabino A., Braegger C.P., Bronsky J., et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J. Crohns Colitis. 2014;8:1179–1207. doi: 10.1016/j.crohns.2014.04.005. [DOI] [PubMed] [Google Scholar]

9.Forbes A., Escher J., Hebuterne X., Klek S., Krznaric Z., Schneider S., Shamir R., Stardelova K., Wierdsma N., Wiskin A.E., et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin. Nutr. 2017;36:321–347. doi: 10.1016/j.clnu.2016.12.027. [DOI] [PubMed] [Google Scholar]

10.Ashton J.J., Gavin J., Beattie R.M. Exclusive enteral nutrition in Crohn’s disease: Evidence and practicalities. Clin. Nutr. 2019;38:80–89. doi: 10.1016/j.clnu.2018.01.020. [DOI] [PubMed] [Google Scholar]

11.Milani C., Duranti S., Bottacini F., Casey E., Turroni F., Mahony J., Belzer C., Delgado Palacio S., Arboleya Montes S., Mancabelli L., et al. The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. Microbiol. Mol. Biol. Rev. 2017;81:e00036-17. doi: 10.1128/MMBR.00036-17. [DOI] [PMC free article] [PubMed] [Google Scholar]

12.Dinan T.G., Cryan J.F. Gut instincts: Microbiota as a key regulator of brain development, ageing and neurodegeneration. J. Physiol. 2017;595:489–503. doi: 10.1113/JP273106. [DOI] [PMC free article] [PubMed] [Google Scholar]

13.Takiishi T., Fenero C.I.M., Camara N.O.S. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. Tissue Barriers. 2017;5:e1373208. doi: 10.1080/21688370.2017.1373208. [DOI] [PMC free article] [PubMed] [Google Scholar]

14.Carding S., Verbeke K., Vipond D.T., Corfe B.M., Owen L.J. Dysbiosis of the gut microbiota in disease. Microb. Ecol. Health Dis. 2015;26:26191. doi: 10.3402/mehd.v26.26191. [DOI] [PMC free article] [PubMed] [Google Scholar]

15.Nell S., Suerbaum S., Josenhans C. The impact of the microbiota on the pathogenesis of IBD: Lessons from mouse infection models. Nat. Rev. Microbiol. 2010;8:564–577. doi: 10.1038/nrmicro2403. [DOI] [PubMed] [Google Scholar]

16.Oka A., Sartor R.B. Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. Dig. Dis. Sci. 2020;65:757–788. doi: 10.1007/s10620-020-06090-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

17.Thomas J.P., Modos D., Rushbrook S.M., Powell N., Korcsmaros T. The Emerging Role of Bile Acids in the Pathogenesis of Inflammatory Bowel Disease. Front. Immunol. 2022;13:829525. doi: 10.3389/fimmu.2022.829525. [DOI] [PMC free article] [PubMed] [Google Scholar]

18.Gevers D., Kugathasan S., Denson L.A., Vazquez-Baeza Y., Van Treuren W., Ren B., Schwager E., Knights D., Song S.J., Yassour M., et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–392. doi: 10.1016/j.chom.2014.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]

19.Khanna S., Raffals L.E. The Microbiome in Crohn’s Disease: Role in Pathogenesis and Role of Microbiome Replacement Therapies. Gastroenterol. Clin. N. Am. 2017;46:481–492. doi: 10.1016/j.gtc.2017.05.004. [DOI] [PubMed] [Google Scholar]

20.Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J. Clin. Investig. 2007;117:514–521. doi: 10.1172/JCI30587. [DOI] [PMC free article] [PubMed] [Google Scholar]

21.Linares R., Frances R., Gutierrez A., Juanola O. Bacterial Translocation as Inflammatory Driver in Crohn’s Disease. Front. Cell Dev. Biol. 2021;9:703310. doi: 10.3389/fcell.2021.703310. [DOI] [PMC free article] [PubMed] [Google Scholar]

22.Geremia A., Arancibia-Carcamo C.V., Fleming M.P., Rust N., Singh B., Mortensen N.J., Travis S.P., Powrie F. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 2011;208:1127–1133. doi: 10.1084/jem.20101712. [DOI] [PMC free article] [PubMed] [Google Scholar]

23.Schmitt H., Neurath M.F., Atreya R. Role of the IL23/IL17 Pathway in Crohn’s Disease. Front. Immunol. 2021;12:622934. doi: 10.3389/fimmu.2021.622934. [DOI] [PMC free article] [PubMed] [Google Scholar]

24.Kamada N., Hisamatsu T., Okamoto S., Chinen H., Kobayashi T., Sato T., Sakuraba A., Kitazume M.T., Sugita A., Koganei K., et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J. Clin. Investig. 2008;118:2269–2280. doi: 10.1172/JCI34610. [DOI] [PMC free article] [PubMed] [Google Scholar]